Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Gynecology

Free Subscription Articles published in Oncogene Retrieve available abstracts of 46 articles: HTML format

Single Articles

February 2026
1. CHENG G, Jiang W, Li Z, Ma Y, et al
   TFAP2C protects against ferroptosis in ovarian cancer through the KEAP1-NRF2 axis by recruiting HDAC1/2.
   Oncogene. 2026 Feb 17. doi: 10.1038/s41388-026-03692.
   PubMed     Abstract available
   
   
   
2. XU J, Shi G, Qin Z, Yin B, et al
   Tumor cell-intrinsic PD-1 in malignant ascites drives ovarian cancer progression via MAPK/ERK signaling.
   Oncogene. 2026 Feb 17. doi: 10.1038/s41388-026-03693.
   PubMed     Abstract available
   
   
   
3. VISWANADHAPALLI S, Lee TK, Elmore S, Sharma G, et al
   Therapeutic optimization of LIPA targeting to induce endoplasmic reticulum stress and cell death in ovarian cancer.
   Oncogene. 2026 Feb 6. doi: 10.1038/s41388-026-03689.
   PubMed     Abstract available
   
   
   January 2026
4. SUN J, Cai X, Yung MMH, Zhou W, et al
   Retraction Note: miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.
   Oncogene. 2026 Jan 16. doi: 10.1038/s41388-026-03676.
   PubMed    
   
   
   December 2025
5. JI F, Yan K, Ding B, Zhu Y, et al
   Dual-target CAR-T therapy for ovarian cancer: synergistic targeting of MSLN and B7H3 enhances anti-tumor efficacy and overcomes antigen heterogeneity.
   Oncogene. 2025 Dec 17. doi: 10.1038/s41388-025-03663.
   PubMed     Abstract available
   
   
   
6. LI Q, Zhang S, Wang M, Yi Q, et al
   Correction: Activated MAFB in ovarian cancer promotes cytoskeletal remodeling and immune microenvironment suppression by interfering with m6A modifications through WTAP competition.
   Oncogene. 2025 Dec 5. doi: 10.1038/s41388-025-03656.
   PubMed    
   
   
   November 2025
7. LIU S, He Y, Ning X, Xu W, et al
   SLC7A5-ERBB2 axis drives olaparib resistance via de novo lipid synthesis in ovarian cancer.
   Oncogene. 2025 Nov 28. doi: 10.1038/s41388-025-03584.
   PubMed     Abstract available
   
   
   October 2025
8. TANG S, Chen K, Zheng F, Fu Z, et al
   High serum LDL promotes EMT and stemness through LDLR/FOXQ1/NF-kappaB1 pathway in epithelial ovarian cancer.
   Oncogene. 2025 Oct 22. doi: 10.1038/s41388-025-03609.
   PubMed     Abstract available
   
   
   
9. WU L, Wu C, He S, Chen Y, et al
   METAP2 inhibits K48-linked ubiquitination of YTHDF2 to promote ovarian cancer progression.
   Oncogene. 2025 Oct 16. doi: 10.1038/s41388-025-03594.
   PubMed     Abstract available
   
   
   September 2025
10. LIU J, Ning J, Wang Y, He X, et al
    FOXA2 sensitizes endometrial carcinoma to progestin-mediated conservative therapy by triggering PR transcriptional activation.
    Oncogene. 2025 Sep 13. doi: 10.1038/s41388-025-03564.
    PubMed     Abstract available
    
    
    
11. HUANG L, Zhu M, Chen M, Ying F, et al
    LEF1 confers resistance to DNA-damaging chemotherapies through upregulation of PARP1 and NUMA1 in ovarian cancer.
    Oncogene. 2025 Sep 10. doi: 10.1038/s41388-025-03561.
    PubMed     Abstract available
    
    
    August 2025
12. LABUDA SE, Broaddus RR, Gladden AB
    ARID1A: gene, protein, and function in endometrial cancer.
    Oncogene. 2025 Aug 18. doi: 10.1038/s41388-025-03539.
    PubMed     Abstract available
    
    
    
13. LI Q, Zhang S, Wang M, Yi Q, et al
    Activated MAFB in ovarian cancer promotes cytoskeletal remodeling and immune microenvironment suppression by interfering with m6A modifications through WTAP competition.
    Oncogene. 2025 Aug 12. doi: 10.1038/s41388-025-03522.
    PubMed     Abstract available
    
    
    July 2025
14. SHEN C, Cao R, Zhou Q, Zhou T, et al
    LINC00654 promotes ovarian cancer progression by facilitating nuclear export of HuR and stabilizing oncogenic mRNAs.
    Oncogene. 2025 Jul 22. doi: 10.1038/s41388-025-03500.
    PubMed     Abstract available
    
    
    May 2025
15. SONG C, Lin Y, Cai C, Tao K, et al
    LOXL2 reduces susceptibility to PARP inhibitors by promoting super-enhancer-regulated DNA damage repair in high-grade serous ovarian cancer.
    Oncogene. 2025 May 31. doi: 10.1038/s41388-025-03466.
    PubMed     Abstract available
    
    
    
16. NARAYANA RVL, Gupta R
    Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment.
    Oncogene. 2025 May 27. doi: 10.1038/s41388-025-03448.
    PubMed     Abstract available
    
    
    
17. ZHANG C, Jiang H, Yuan L, Liao Y, et al
    Correction: CircVPRBP inhibits nodal metastasis of cervical cancer by impeding RACK1 O-GlcNAcylation and stability.
    Oncogene. 2025 May 15. doi: 10.1038/s41388-025-03440.
    PubMed    
    
    
    April 2025
18. ZHU Y, Abedini A, Rodriguez GM, McCloskey CW, et al
    Loss of LATS1 and LATS2 promotes ovarian tumor formation by enhancing AKT activity and PD-L1 expression.
    Oncogene. 2025 Apr 12. doi: 10.1038/s41388-025-03387.
    PubMed     Abstract available
    
    
    
19. LI Y, Chen Z, Gao Y, Liu Y, et al
    SNRPB-mediated regulation of DDX39A splicing promotes ovarian cancer progression by regulating alpha6 integrin subunit expression.
    Oncogene. 2025 Apr 11. doi: 10.1038/s41388-025-03386.
    PubMed     Abstract available
    
    
    
20. WAGNER V, Morton M, Dorayappan KDP, Gonzalez A, et al
    Circulating extracellular vesicles protein expression for early prediction of platinum-resistance in high-grade serous ovarian cancer.
    Oncogene. 2025 Apr 10. doi: 10.1038/s41388-025-03382.
    PubMed     Abstract available
    
    
    March 2025
21. ZHAO X, Lai H, Li G, Qin Y, et al
    Rictor orchestrates beta-catenin/FOXO balance by maintaining redox homeostasis during development of ovarian cancer.
    Oncogene. 2025 Mar 25. doi: 10.1038/s41388-025-03351.
    PubMed     Abstract available
    
    
    
22. WANG J, Yang F, Chen Y, Xing Y, et al
    A positive feedback loop of OTUD1 and c-Jun driven by leptin expedites stemness maintenance in ovarian cancer.
    Oncogene. 2025 Mar 19. doi: 10.1038/s41388-025-03342.
    PubMed     Abstract available
    
    
    
23. ZHAI F, Li Y, Zheng J, Yan C, et al
    SPOP/NOLC1/B4GALT1 signaling axis enhances paclitaxel resistance in endometrial cancer by inducing O-dysglycosylation.
    Oncogene. 2025 Mar 17. doi: 10.1038/s41388-025-03347.
    PubMed     Abstract available
    
    
    
24. FANG D, Chen H, Zhu JY, Wang W, et al
    Editorial Expression of Concern: Epithelial-mesenchymal transition of ovarian cancer cells is sustained by Rac1 through simultaneous activation of MEK1/2 and Src signaling pathways.
    Oncogene. 2025 Mar 3. doi: 10.1038/s41388-025-03333.
    PubMed    
    
    
    February 2025
25. XI Q, Kunita A, Ogawa M, Ka M, et al
    Cyclin E1 overexpression sensitizes ovarian cancer cells to WEE1 and PLK1 inhibition.
    Oncogene. 2025 Feb 24. doi: 10.1038/s41388-025-03312.
    PubMed     Abstract available
    
    
    
26. STEWART J, Krastev DB, Brough R, Zatreanu D, et al
    PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma.
    Oncogene. 2025 Feb 12. doi: 10.1038/s41388-024-03265.
    PubMed     Abstract available
    
    
    January 2025
27. DONG P, Xiong Y, Yu J, Chen L, et al
    Editorial Expression of Concern: Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer.
    Oncogene. 2025 Jan 29. doi: 10.1038/s41388-025-03285.
    PubMed    
    
    
    
28. WANG M, Yan Q, Song Y, Zhang Z, et al
    Correction: Loss-of-function mutations of SOX17 lead to YAP/TEAD activation-dependent malignant transformation in endometrial cancer.
    Oncogene. 2025 Jan 27. doi: 10.1038/s41388-025-03280.
    PubMed    
    
    
    
29. HAN X, Xia L, Wu Y, Chen X, et al
    m6A-modified circSTX6 as a key regulator of cervical cancer malignancy via SPI1 and IL6/JAK2/STAT3 pathways.
    Oncogene. 2025 Jan 15. doi: 10.1038/s41388-024-03260.
    PubMed     Abstract available
    
    
    December 2024
30. ZHAI X, Shen N, Guo T, Wang J, et al
    SPTLC2 drives an EGFR-FAK-HBEGF signaling axis to promote ovarian cancer progression.
    Oncogene. 2024 Dec 7. doi: 10.1038/s41388-024-03249.
    PubMed     Abstract available
    
    
    
31. CHIA ML, Bulat F, Gaunt A, Ros S, et al
    Metabolic imaging distinguishes ovarian cancer subtypes and detects their early and variable responses to treatment.
    Oncogene. 2024 Dec 6. doi: 10.1038/s41388-024-03231.
    PubMed     Abstract available
    
    
    
32. DUAN Q, Wang W, Xiong H, Xiao J, et al
    JAK2/ULK1 axis promotes cervical cancer progression by autophagy induction and SRPK1 phosphorylation.
    Oncogene. 2024 Dec 4. doi: 10.1038/s41388-024-03246.
    PubMed     Abstract available
    
    
    October 2024
33. SAKAUE T, Dorayappan KDP, Zingarelli R, Khadraoui W, et al
    Obesity-induced extracellular vesicles proteins drive the endometrial cancer pathogenesis: therapeutic potential of HO-3867 and Metformin.
    Oncogene. 2024 Oct 16. doi: 10.1038/s41388-024-03182.
    PubMed     Abstract available
    
    
    
34. SHI J, Zhou R, Wang S, Liu Y, et al
    NEU4-mediated desialylation enhances the activation of the oncogenic receptors for the dissemination of ovarian carcinoma.
    Oncogene. 2024 Oct 14. doi: 10.1038/s41388-024-03187.
    PubMed     Abstract available
    
    
    
35. LI Y, Yang H, Li A, Chen B, et al
    CypA/TAF15/STAT5A/miR-514a-3p feedback loop drives ovarian cancer metastasis.
    Oncogene. 2024 Oct 14. doi: 10.1038/s41388-024-03188.
    PubMed     Abstract available
    
    
    
36. LIU Y, Li J, Xu J, Long Y, et al
    m(6)A-driven NAT10 translation facilitates fatty acid metabolic rewiring to suppress ferroptosis and promote ovarian tumorigenesis through enhancing ACOT7 mRNA acetylation.
    Oncogene. 2024 Oct 10. doi: 10.1038/s41388-024-03185.
    PubMed     Abstract available
    
    
    
37. SUN X, Ye G, Li J, Yuan L, et al
    The tumor suppressor Parkin exerts anticancer effects through regulating mitochondrial GAPDH activity.
    Oncogene. 2024;43:3215-3226.
    PubMed     Abstract available
    
    
    September 2024
38. SANG X, Han J, Wang Z, Cai W, et al
    SGK1 suppresses ferroptosis in ovarian cancer via NRF2-dependent and -independent pathways.
    Oncogene. 2024 Sep 21. doi: 10.1038/s41388-024-03173.
    PubMed     Abstract available
    
    
    
39. CHEN J, Shan W, Jia Q, Chen Y, et al
    USP33 facilitates the ovarian cancer progression via deubiquitinating and stabilizing CBX2.
    Oncogene. 2024 Sep 10. doi: 10.1038/s41388-024-03151.
    PubMed     Abstract available
    
    
    August 2024
40. ONJI H, Tate S, Sakaue T, Fujiwara K, et al
    Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks.
    Oncogene. 2024;43:2475-2489.
    PubMed     Abstract available
    
    
    June 2024
41. GHEZELAYAGH TS, Kohrn BF, Fredrickson J, Krimmel-Morrison JD, et al
    TP53 somatic evolution in cervical liquid-based cytology and blood from individuals with and without ovarian cancer and BRCA1 or BRCA2 germline mutations.
    Oncogene. 2024 Jun 25. doi: 10.1038/s41388-024-03089.
    PubMed     Abstract available
    
    
    May 2024
42. PATTERSON MR, Meijers AS, Ryder EL, Wootton LM, et al
    E7-mediated repression of miR-203 promotes LASP1-dependent proliferation in HPV-positive cervical cancer.
    Oncogene. 2024 May 24. doi: 10.1038/s41388-024-03067.
    PubMed     Abstract available
    
    
    
43. ZHANG C, Xu Y, Zhu X, Zhang X, et al
    Phosphorylation of FOXK2 at Thr13 and Ser30 by PDK2 sustains glycolysis through a positive feedback manner in ovarian cancer.
    Oncogene. 2024 May 11. doi: 10.1038/s41388-024-03052.
    PubMed     Abstract available
    
    
    April 2024
44. SHAN W, Peng W, Chen Y, Wang Y, et al
    GSK3beta and UCHL3 govern RIPK4 homeostasis via deubiquitination to enhance tumor metastasis in ovarian cancer.
    Oncogene. 2024 Apr 25. doi: 10.1038/s41388-024-03040.
    PubMed     Abstract available
    
    
    
45. CHEN H, Lee LJ, Vincent KM, Xu Z, et al
    Transcription factor ZIC2 regulates the tumorigenic phenotypes associated with both bulk and cancer stem cells in epithelial ovarian cancer.
    Oncogene. 2024 Apr 9. doi: 10.1038/s41388-024-03026.
    PubMed     Abstract available
    
    
    
46. WEI Y, Chen Z, Li Y, Song K, et al
    The splicing factor WBP11 mediates MCM7 intron retention to promote the malignant progression of ovarian cancer.
    Oncogene. 2024 Apr 1. doi: 10.1038/s41388-024-03015.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum